Premium
Parathyroid hormone‐like peptide in normal and neoplastic mesothelial cells
Author(s) -
McAuley P.,
Asa S. L.,
Chiu B.,
Henderson J.,
Goltzman D.,
Drucker D. J.
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19901101)66:9<1975::aid-cncr2820660921>3.0.co;2-3
Subject(s) - mesothelioma , mesothelial cell , medicine , pathogenesis , immunohistochemistry , malignancy , pathology , parathyroid hormone , cancer research , calcium
Mesothelioma has not been commonly reported as a cause of hypercalcemia of malignancy. We have studied a patient with malignant mesothelioma and hypercalcemia in association with elevated plasma concentrations of parathyroid hormone‐like peptide (PLP). Immunohistochemical analysis of the tumor and seven of eight other mesotheliomas that were not associated with hypercalcemia revealed the presence of PLP cytoplasmic immunopositivity. PLP immunopositivity was also detected in normal and reactive mesothelial cells. The results of these studies suggest that PLP immunoreactivity is common in normal and neoplastic mesothelial cells and raises the possibility that PLP production may play a role in the pathogenesis of hypercalcemia associated with mesothelioma.